Century Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Century Therapeutics's earnings have been declining at an average annual rate of -1.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 33.7% per year.

Belangrijke informatie

-1.8%

Groei van de winst

82.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	33.7%
Rendement op eigen vermogen	-59.2%
Nettomarge	-6,437.4%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 20

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

Opbrengsten en kosten

Hoe Century Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:IPSC Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	2	-131	35	0
31 Mar 24	1	-133	35	0
31 Dec 23	2	-137	35	0
30 Sep 23	2	-129	34	0
30 Jun 23	5	-127	33	0
31 Mar 23	6	-125	33	0
31 Dec 22	5	-131	32	0
30 Sep 22	5	-127	30	0
30 Jun 22	2	-123	28	0
31 Mar 22	1	-115	24	0
31 Dec 21	0	-96	19	0
30 Sep 21	0	-83	16	12
30 Jun 21	0	-70	12	23
31 Mar 21	0	-62	10	32
31 Dec 20	0	-54	9	40

Kwaliteitswinsten: IPSC is currently unprofitable.

Groeiende winstmarge: IPSC is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: IPSC is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.

Versnelling van de groei: Unable to compare IPSC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: IPSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).

Rendement op eigen vermogen

Hoge ROE: IPSC has a negative Return on Equity (-59.16%), as it is currently unprofitable.

Century Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

New minor risk - Market cap size

Century Therapeutics, Inc. Appoints Chad Cowan as Chief Scientific Officer, Effective October 1, 2024

Century Therapeutics, Inc. Appoints Morgan Conn as Chief Financial Officer, Effective October 14, 2024

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Price target decreased by 9.2% to US$17.89

Price target decreased by 8.6% to US$18.00

Chief Scientific Officer recently sold US$55k worth of stock

Chief Scientific Officer exercised options and sold US$351k worth of stock

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Elipse-1 Trial Evaluating Cnty-101 in Relapsed or Refractory Cd19 Positive B-Cell Lymphomas

Price target decreased to US$20.30

Consensus revenue estimates increase by 26%

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Preclinical Data At the SITC 37Th Annual Meeting and Provides Pipeline Updates

Price target decreased to US$22.44

Casdin Capital Engages in Discussions with Century Therapeutics

Century Therapeutics, Inc. Announces Board Changes

Century Therapeutics, Inc. Receives Study May Proceed Notification from FDA for CNTY-101

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Consensus revenue estimates fall by 20%

Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 2,133%

High number of new and inexperienced directors

Century Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Data At the 63Rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden